RadarScreen, a novel yeast-based screening system allowing rapid and cost-effective identification of genotoxic compounds in early stage drug discovery

Potential DNA damaging compounds can be detected in a high-throughput cellular screen using RadarScreen, a method developed by reMYND and based on the sensitivity of a reporter gene to DNA damage in eukaryotic cells. reMYND’s RadarScreen assay is fully validated and:

• Identifies genotox liabilities of compounds or its metabolites more sensitively, user friendly and cost-effectively than any of the currently available screens of its kind
• Is especially suitable for the identification of clastogenic compounds and highly predictive of in vitro SCE and micronucleus tests
• Allows genotox screening early on in the discovery process